CorticoMetrics seeks to improve the state of clinical decision making in neuroradiology, augmenting qualitative assessment with quantitative analysis of magnetic resonance imaging (MRI) scans of the brain. CorticoMetrics is targeting a number of neurological disorders and conditions that affect millions of people worldwide, including epilepsy, dementia, multiple sclerosis, traumatic brain injury, and hydrocephalus. CorticoMetrics is a privately-held company composed of a team with extensive scientific, engineering, management and business experience in neuroimaging and computing technology industries. Launched in 2012 to spin-off technology developed at the Martinos Center for Biomedical Imaging at the Massachusetts General Hospital, CorticoMetrics continues to work with MGH in research and product development through several NIH SBIR/STTR grant-funded projects.
re:THINQ, created by CorticoMetrics, generates volume and thickness-based measurements for over 50 human brain structures from T1-weighted MRI images. This includes both gray and white matter volumes for cortical and subcortical structures as well as cortical gray matter thickness values for all major gyri. Information is delivered to the end-user in a PDF report containing absolute measures, interhemispheric asymmetry measures, and percentile estimates as compared to a healthy normative set of adult human brain data. Visual representations of the cortical surface demonstrate patterns of abnormal cortical thinning or thickening, and graphical representations of subcortical structure volumes depict normative values across the adult age range. The information included in the re:THINQ PDF report can also be exported in CSV format.
The foundation of re:THINQ software technology is FreeSurfer, a high-quality suite of automated neuroimaging tools for brain morphometry, developed at Massachusetts General Hospital (MGH) for research purposes. re:THINQ is the first step by CorticoMetrics in bringing these tools to clinical practice.
re:THINQ is for Research Use only, and is not cleared or approved by the FDA for detection, diagnosis or treatment of any neurological disorder or condition. CorticoMetrics is working on a regulatory approved clinical product.